公开(公告)号：US20180072714A1

公开(公告)日：2018-03-15

申请号：US15558824

申请日：2016-03-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Saleh Ahmed ,  Gregory Barker ,  Hannah Canning ,  Richard Davenport ,  David Harrison ,  Kerry Jenkins ,  David Livermore ,  Susanne Wright ,  Natasha Kinsella

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, Y1, Y2, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10287286B2

公开(公告)日：2019-05-14

申请号：US15558824

申请日：2016-03-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Saleh Ahmed ,  Gregory Barker ,  Hannah Canning ,  Richard Davenport ,  David Harrison ,  Kerry Jenkins ,  David Livermore ,  Susanne Wright ,  Natasha Kinsella

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, Y1, Y2, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US20150376179A1

公开(公告)日：2015-12-31

申请号：US14766520

申请日：2014-02-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： David Livermore ,  Kathryn White ,  Miles Congreve ,  Giles Brown ,  Michael O'Brien

IPC: C07D417/14 ,  A61K31/4545 ,  A61K31/55 ,  A61K45/06 ,  A61K31/454 ,  A61K31/506 ,  C07D413/14 ,  C07D401/14 ,  C07D409/14

CPC classification number: C07D417/14 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/55 ,  A61K45/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

Abstract translation: 本发明提供式（I）的毒蕈碱M4受体激动剂及其药学上可接受的盐，其中m，n，p，q，R，R 2和R 3如说明书中所定义，其制备方法，含有它们的药物组合物和 它们用于治疗诸如精神分裂症，阿尔茨海默病和各种认知障碍等疾病以及治疗或缓解疼痛。

公开(公告)号：US09750748B2

公开(公告)日：2017-09-05

申请号：US14652484

申请日：2013-12-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： William Farnaby ,  Charlotte Fieldhouse ,  Katherine Hazel ,  Catrina Kerr ,  Natasha Kinsella ,  David Livermore ,  Kevin Merchant ,  David Miller

IPC: A61K31/55 ,  C07D405/04 ,  A61K31/501 ,  C07D403/04 ,  C07D237/20 ,  C07D401/04 ,  A61K45/06 ,  A61K31/50 ,  C07D237/16 ,  C07D237/22 ,  A61K31/277 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/554 ,  A61K33/00

CPC classification number: A61K31/55 ,  A61K31/277 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/554 ,  A61K33/00 ,  A61K45/06 ,  C07D237/16 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  A61K2300/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.